Review of the safety and efficacy of ustekinumab

  • Scherl E
  • Kumar S
  • Warren R
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • E J Scherl

  • S Kumar

  • R U Warren

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free